



SJR Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

Home Journal Rankings Country Rankings Viz Tools Help About Us

International Journal of Pharmaceutical Research

Discontinued in Scopus as of 2021



COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
India  	Pharmacology, Toxicology and Pharmaceutics — Pharmaceutical Science — Pharmacology, Toxicology and Pharmaceutics (miscellaneous)	Advanced Scientific Research	26
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	09752366	2010-2021	Homepage How to publish in this journal info@ijpronline.com

SCOPE


International Journal of Pharmaceutical Research (IJPR) is an intentional Journal which is published quarterly in English. Journal publishes papers, review articles, and short communications dealing with drug controlled release systems, pharmacodynamics, pharmacokinetics, pharmacogenomics, biopharmaceutics, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, pharmaceutical engineering and materials science. Pharmaceutical Chemistry, Pharmaceutical Technology, pharmacognosy, natural product research, pharmaceutics, novel drug delivery, pharmaceutical & medicinal chemistry, computational chemistry and molecular drug design, pharmacology, pharmaceutical analysis, pharmacy practice, clinical and hospital pharmacy etc. IJPR would take much care in making your article published without much delay with your kind cooperation. IJPR hopes that Researchers, Research scholars, Academician, Industrialists etc. would make use of this research publications for the development of pharmaceutical science and technology.

 Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS  options 

1 Journal of Pharmaceutical Sciences and Research IND 59% similarity	2 International Journal of Research in Pharmaceutical IND 57% similarity	3 Journal of Global Pharma Technology IND 47% similarity	4 Biomedical and Pharmacology Journal IND 42% similarity	5 Journal of Applied Pharmaceutical Science IND 41% similarity
--	--	--	--	--



Metrics based on Scopus® data as of April 2023

R **Raveendra Gudodagi** 1 year ago

Dear all,
Please do not submit your hard work to this journal. This journal is not indexed by Scopus from 2020. However I have a paper published in this journal in 2020, but they have not submitted to scopus data base.

← reply

K **KN** 1 month ago

Please can you contact me via my email?

H **HOSSEIN ESMAELI** 2 years ago

Hi
I published an article in your magazine, but unfortunately it was not accepted due to the deletion of the magazine's Q number. What is the reason for its deletion?

← reply



Melanie Ortiz 2 years ago

SCImago Team

Dear Hossein, thank you very much for your participation.
Our data come from Scopus/Elsevier, which offers an annual copy of their database. We understand that, since the date indicated by Scopus/Elsevier, the journal is no longer indexed in its database. While the citation window is still active, we can show indicators of the journal (up to three years).
Best Regards, SCImago Team



Five Years Citation in Google scholar (2016 - 2020) is. 1451 * IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *

**INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH**A Step Towards Excellence
Published by : Advanced Scientific Research

ISSN

0975-2366

[Home](#) [About Us](#) [Editorial Board](#) [Instruction to Authors](#) [Current Issue](#) [Article In Press](#) [Table Of Contents](#)**CURRENT ISSUE**

volume 15, Issue 3, July - Sept, 2023

ARTICLE IN PRESS

No Data found.

ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

[Click here to Download](#)IJPR 9[3] JULY -
SEPTEMBER 2017
SPECIAL ISSUE

July - September 9[3] 2017

[Click to download](#)

Q Manuscript Status...

GO

Manuscript Status**RESEARCH****The Effect of L-Arginine on Diameter of Spiral Artery and Fetal Weight between Normal Pregnant Mice and Preeclampsia Mouse Models**
ADITIAWARMAN, MANGGALA PASCA WARDHANA, LALITA EKA PERVITA
SARI, HERMANTO TRI JOEWONO
Volume 12, Issue 4**Embase[®]****ONLINE SUBMISSION**[Click here for Online Submission](#)**USER LOGIN** Author Reviewer
 Editor SubscriberUsername Password [Login](#) | [Register](#)**NEWS & EVENTS****International Journal of
Pharmaceutical Research**Not yet assigned
quartile

SJIR 2022

0



powered by scimagojr.com

Terms and Conditions[Disclaimer](#)[Refund Policy](#)[Instructions for Subscribers](#)[Privacy Policy](#)**Copyrights Form****0.12**2018
CiteScore

8th percentile

Powered by **Scopus****Google Scholar**

Five Years Citation in Google scholar (2016 - 2020) is. 1451 * IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *



INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

ISSN

0975-2366

A Step Towards Excellence

Published by : Advanced Scientific Research

Home

About Us

Editorial Board

Instruction to Authors

Current Issue

Article In Press

Table Of Contents

CURRENT ISSUE

volume 15, Issue 3, July -
Sept, 2023

ARTICLE IN PRESS

No Data found.

ADOBE READER

(Require Adobe Acrobat Reader to
open, If you don't have Adobe
Acrobat Reader)



[Click here to Download](#)

IJPR 9[3] JULY -
SEPTEMBER 2017
SPECIAL ISSUE

July - September 9[3] 2017

[Click to download](#)

Q Manuscript Status...

GO

EDITORIAL BOARD

Editor-in-Chief

Dr. Dhiren P Shah

info@ijpronline.com

Professor & Principal

Shree Naranjibhai Labhai Patel College of Pharmacy,

Associate Editors

Dr. Vineet C Jain

Vcjainsdpc156@gmail.com

Professor & Principal

Bhagwan Mahavir College of Pharmacy,,

Dr.KUMAR SUBRAMANI

Ksubramanis@augusta.edu

Departments of Pharmacology and Toxicology

*Medical college of Georgia Augusta University formerly (Georgia Regents
University), Augusta*

Dr.Ayad F. Alkaim

ayad_alkaim@yahoo.com

University of Babylon,

College of Science for Women, Babylon, Iraq , Scopus Author ID: 55255310600

Advisory Board (India).

Dr. G K Jani

Girishkjani2002@yahoo.com

Professor

K B Raval College of

Pharmacy, Scopus Author ID:

6507785159

Dr. B N Suhagia

patelhary@rediffmail.com

Professor & Principal

Dharmasi Desai Institute of

Technology, Scopus Author

Id=6508322131

Dr. S A Shah

Shailesh.shah@utu.ac.in

Professor & Principal

Uka Tarsadia University,

Maliba Pharmacy College,

Surat, Scopus Author ID:

7403888964

Dr. D D Santani

Dr. P U Patel

Dr. P B Shah

Dr. M G Saraliya

Dr. D M Patel

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. S P Bhatt

Sunrisedeep78@gmail.com

Associate Professor

K B Institute of Pharmaceutical

Education & Research

Paresh Bhagvatiprasad Shah,

Pbshah23@rediffmail.com

Associate Professor

Shri B. M. Shah College of

Pharmacy, Modasa, Scopus

AuthorId=15763373500

Dr. A H Akabari

ashokakabari@yahoo.com

Associate Professor

C K Pithawalla Institute of

Pharmaceutical Science &

Research

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen

Dr. D.J. Sen



Embase®



ONLINE SUBMISSION

[Click here for Online Submission](#)

USER LOGIN

Author Reviewer
 Editor Subscriber

Username

Password

[Login](#) | [Register](#)

NEWS & EVENTS

International Journal of
Pharmaceutical Research

Not yet assigned
quartile

SJR 2022

0

powered by scimagojr.com

Terms and Conditions

[Disclaimer](#)

[Refund Policy](#)

[Instructions for Subscribers](#)

[Privacy Policy](#)

Copyrights Form

0.12

2018
CiteScore

8th percentile

Powered by Scopus

Google Scholar



Dr. A K Saluja	Dr. V V Jogani	Dr. C J Shishoo
Dr. S K Jain	Dr. P J Shah	Dr. Prasanna Reddy Y B
Dr. A K Seth	Dr. Maulik Panchal	Dr. Anurekha Jain
Dr. T R Desai	Mrs. Kirti Patel	Dr. J R Chavda
Dr. Rajesh Kasara	Mrs. Kalpana Patel	Dr. C N Patel
Dr. Abhay Dharamsi	Mr. V D Prajapati	Dr. Angshu Banerjee <i>angshubanerjee@rediffmail.com</i>
Dr. Sunil Jalalpure	Dr. Anil Jadhav	Dr. Veena K <i>vkotabagi@gmail.co</i>
Dr. Shailendra Lariya	Dr. B S Nayak	Dr. H P Dalvadi <i>hpdalvadi@gmail.com</i> <i>Associate Professor</i> <i>Rofel & Shri G M Bilakhia</i> <i>College of Pharmacy</i>
Dr. J K Patel	Dr. K K Dholvani	DR. N. G. RAGHAVENDRA RAO <i>nraghu@rediffmail.com</i> <i>PROFESSOR AND DIRECTOR</i> <i>GRD [PG] Institute of</i> <i>Management and Technology,</i>

Advisory Board (International)

Dr. Parijat Kanaujia (Singapore) <i>ices@a-star.edu.sg</i> <i>VP, Injectables Product Development</i> <i>VALLAURIX PTE LTD part of the</i> <i>CLINUVEL Group, 1 Science Park Road,</i> <i>#05-13/14, The Capricorn, Singapor</i>	Dr. Parvaneh Rahimi-Moghaddam (Iran) <i>rahimi.p@iums.ac.ir</i> <i>Associate Professor</i> <i>IRAN University of Medical Sciences</i> <i>(IUMS)</i>
Dr. Vikas Jaitely (UK)	Mr. Nitesh G Sonani
Dr. Yogesh Katare (Canada)	Mr. Manish A Patel
Dr. Ruchi Katare (Canada)	Dr. A. Omri (Sudbury, Canada) <i>aomri@laurentian.ca</i> <i>Department of Chemistry and Biochemistry</i> <i>Laurentian University, Sudbury ON,</i> <i>Canada Author ID: 35492680500</i>
Dr. Vivek Mishra (Canada)	Dr. Priyanka Bhatt <i>psbhatt@health.usf.edu</i> <i>Department of Pharmaceutical Sciences</i> <i>College of Pharmacy University of South</i> <i>Florida</i>
Mr. Hareesh Shah (USA)	Yasamin Hamza Sharif <i>Department of Obstetrics and Gynecology</i> <i>University of Al-Qadisiyah</i>
Dr. N. Venkatesan (USA)	

ENHANCED BY



01510918

Research Article

The Effect of L-Arginine on Diameter of Spiral Artery and Fetal Weight between Normal Pregnant Mice and Preeclampsia Mouse Models

ADITIAWARMAN*, MANGGALA PASCA WARDHANA, LALITA EKA PERVITA SARI, HERMANTO TRI JOEWONO

Department of Obstetrics and Gynecology, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia

*Corresponding Author

Email ID: aditiawarman@fk.unair.ac.id

Received: 08.04.20, Revised: 22.05.20, Accepted: 13.06.20

ABSTRACT

L-Arginine is a semi-essential amino acid, which is one of the nitric oxide (NO) synthesis substrates. This compound has a role in the L-Arginine-NO pathway in preeclampsia. This study determined the effect of L-Arginine on the diameter of the spiralis artery and fetal weight in normal pregnant mice and preeclampsia mice model. A true experimental study with randomized post-test-only control group using Swiss Mus musculus divided into 3 groups. There were normal pregnant mice group (K-), preeclampsia mouse model group (K+), and preeclampsia mouse models with L-Arginine group (P). The mean of fetal weight of each mouse was calculated and measured the diameter of the spiralis artery from placental. The mean diameter of the spiral arteries of the groups (K-), (K+) and (P) was $221.7500 \pm 70.2498 \mu\text{m}$, $159.4333 \pm 30.2653 \mu\text{m}$, and $277.3222 \pm 54.5503 \mu\text{m}$, respectively. There were significant differences between groups (K-) and (K+) ($p = 0.024$), groups (K-) and (P) ($p = 0.047$), and between groups (K+) and (P) ($p = 0.000$). Meanwhile, the mean fetal weight of the groups (K-), (K+) and (P) was $0.6733 \pm 0.3145\text{g}$, $0.6222 \pm 0.2838\text{g}$, and $0.7589 \pm 0.3444\text{g}$, respectively. There were no significant differences between groups (K-) and (K+) ($p = 0.722$), between groups (K-) and (P) ($p = 0.590$), and between groups (K+) and (P) ($p = 0.372$). L-Arginine has been proven effective in repairing endothelial damage and was seen from the diameter of the spiralis artery and fetal weight in preeclampsia mouse models.

Keywords: L-Arginine, preeclampsia, spiral artery, fetal weight

INTRODUCTION

Preeclampsia is a significant factor in maternal and fetal morbidity and mortality, especially in developing countries, and occurs in 2-8% of all pregnant women in the world (1-3). In developing countries, the maternal mortality rate reaches 15% compared to 0-1.8% in developed countries, due to limited access to health facilities (4). Preeclampsia is the third leading cause of death along with infection and bleeding (5). These complications increase in high-risk pregnant women, such as morbid obesity and vitamin D deficiency (6,7). In Dr. Soetomo Hospital, Surabaya, within 2 years preeclampsia-eclampsia accounted for 1106 cases or 21% of 5266 deliveries (8).

In preeclampsia, endothelial dysfunction results in increased vascular resistance, platelet aggregation, and activation of the coagulation system. These factors are associated with abnormal placentation (9). Abnormal placentation is characterized by poor invasion of trophoblasts in uterine vascularization.

Failure of trophoblast invasion will result in changes in the spiral arteries, resulting in a decrease in uteroplacental blood flow and intimal hyperplasia and atherosclerosis (10-13). This abnormal placentation condition causes vasoconstriction and hypoperfusion, then triggers the formation and release of molecules, such as soluble fms-like tyrosine kinase 1 (sFlt-1). sFlt-1 inhibits angiogenic factors, such as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), thus causing an imbalance between angiogenesis and antiangiogenesis factors and in the final condition will cause endothelial dysfunction (9,14). In addition, the PlGF level examination can be used as a predictor of early-onset preeclampsia (15)

L-Arginine as a precursor of nitric oxide (NO) is a semi-essential amino acid whose production is inadequate when the need for NO production increases as in some pregnancy conditions with specific pathologies. L-Arginine concentrations are also known to decrease significantly in

preeclampsia compared to normal pregnant women which shows the potential for NO production disruption (16). L-Arginine has a role in increasing the secretion of growth hormone releasing hormone, thus causing an increase in growth hormone in plasma that affects somatic growth. L-Arginine is also said to have a significant role in fetal growth by stimulating insulin secretion and as a precursor for polyamine synthesis and NO production (17). L-Arginine administration can also increase body weight, uterus, placenta, and fetus (18).

The difference in the incidence and mortality of preeclampsia in developed and developing countries can also be caused by differences in nutritional and nutritional status as one of the important problems in developing countries. Experimental research on supplementation or simple and inexpensive medicines can be a way out of efforts to reduce morbidity and mortality in preeclampsia (19). Based on the role of L-Arginine, this study aimed to analyze the effect of L-Arginine on the diameter of the spiral arteries and fetal body weight in normal pregnant mice and preeclampsia pregnant mouse models.

METHODS

The present study was a true experimental with randomized post-test-only control group, using Swiss strain *Mus musculus*. The sample of the study is 3-month-old pregnant female *Mus musculus* Swiss strain, healthy, and weighing 20-30 grams meeting the inclusion and exclusion criteria. The study sample was divided into three groups, with each group totaling nine mice. This study used three groups of mice: normal pregnant mice (K-),

preeclampsia mouse models without L-Arginine (K+), and preeclampsia mouse models with L-Arginine (P) to analyze differences in fetal body weight and diameter of the spiral arteries in each group and analyze the role of L-Arginine, seen in fetal weight gain and diameter of the spiral arteries in the preeclampsia pregnant mice group given L-Arginine therapy. In group P, L-Arginine was given 200 mg/KgBW/day orally on days 6-14, and placebo was given in the K- and K+ groups. The termination was carried out in all groups at the end of the second trimester (where manifestations of preeclampsia and spiral artery remodeling had occurred), carried out on the 16th day of pregnancy. Researchers calculated the average fetal body weight of each mouse and measured the diameter of the spiral arteries from mice placental, which had been processed into paraffin blocks and stained with Hematoxylin and Eosin. This study had ethical clearance from the ethical committee of the Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia. The data were analyzed with SPSS 25 with unpaired T-test and Kruskal-Wallis.

RESULTS

The mean diameter of the spiral arteries was obtained in the group (K-) $221.7500 \pm 70.2498 \mu\text{m}$, (K+) $159.4333 \pm 30.2653 \mu\text{m}$, and (P) $277.3222 \pm 54.5503 \mu\text{m}$ (Table 1). Statistically, significant differences were obtained between groups (K-) and (K+) ($p = 0.024$), between groups (K-) and (P) ($p = 0.047$), and between groups (K+) and (P) ($p = 0.000$) as seen in Table 2.

Table 1: Comparison of mean spiral artery diameters between groups of mice

Groups	Mean \pm SD (μm)	Median (Min-Max) (μm)	P
K-	221.7500 \pm 70.2498	202.1200 (148.65-354.88)	0.001
K+	159.4333 \pm 30.2653	141.7700 (130.07-206.56)	
P	277.3222 \pm 54.5503	278.4700 (208.70-392.47)	

(K-): normal pregnant mice; (K+): preeclampsia mouse models without L-Arginine; (P): preeclampsia mouse models with L-Arginine

Table 2: Analysis of differences in diameter of the spiral arteries between groups of mice

Groups	p
K- vs. K+	0.024
K- vs. P	0.047
K+ vs. P	0.000

(K-): normal pregnant mice; (K+): preeclampsia mouse models without L-Arginine; (P): preeclampsia mouse models with L-Arginine

Meanwhile, Table 3 displays the mean fetal weight of each group. The mean fetal weight obtained in the groups (K-) was 0.6733 ± 0.3145 gram, (K+) was 0.6222 ± 0.2838 gram, and (P) was 0.7589 ± 0.3444 gram. There were no statistically

significant differences between groups (K-) and (K+) ($p = 0.722$), between groups (K-) and (P) ($p = 0.590$), and between groups (K+) and (P) ($p = 0.372$).

Table 3: Comparison of mean fetal weight between groups of mice

Groups	Mean±SD (gram)
K-	0.6733 ± 0.3145
K+	0.6222 ± 0.2838
P	0.7589 ± 0.3444
(K-): normal pregnant mice; (K+): preeclampsia mouse models without L-Arginine; (P): preeclampsia mouse models with L-Arginine	

Table 4: Analysis of differences in mean fetal weight between groups of mice

Group	p
K- vs K+	0.722
K- vs P	0.590
K+ vs P	0.372
(K-): normal pregnant mice; (K+): preeclampsia mouse models without L-Arginine; (P): preeclampsia mouse models with L-Arginine	

DISCUSSION

Research using the Swiss strain *Mus musculus* models of preeclampsia proves that the administration of L-Arginine in pregnant preeclampsia mouse models can increase the size of the diameter of the spiral arteries and fetal body weight compared to preeclampsia pregnant mice without L-Arginine and normal pregnant mice. The results in this study are in accordance with previous studies observing the effect of L-Arginine on the thickness of the spiral artery walls in mice with preeclampsia models. As the thickness of the intima becomes thicker, the diameter of the spiral arteries will narrow. The administration of L-Arginine is effective in repairing endothelial damage by reducing hyperplasia and atherosclerosis in the spiral arteries, thereby reducing the thickness of the walls of the spirals in the preeclampsia mice. (20). The pathology of the placenta in hypertension in pregnancy reflects changes in uteroplacental insufficiency, such as massive multifocal infarction, sinusitis, thickening of the membrane basement, villous stromal fibrosis, and calcification. Changes in the placenta in hypertension in pregnancy will affect fetal growth and nutrition in the womb (21). In preeclampsia, there are narrowing of the lumen of the arterial spiral (average diameter 200 nm, in normal pregnancies, average diameter 500 nm)

and also a decrease 2-3 times lower in placental perfusion (5).

L-Arginine is considered a semi-essential amino acid because endogenous synthesis does not adequately meet the needs during pregnancy. Vasodilatation failure is the case with preeclampsia, and oral L-Arginine supplementation during pregnancy can increase vasodilatation through increased NO production, although research is still needed with larger samples. (22). A preclinical study conducted on mice also showed that L-Arginine reduced the incidence of hypertension in response to a reduction in uterine perfusion pressure in pregnant mice, suggesting that L-Arginine supplementation might be beneficial in management in cases of preeclampsia. In humans, administration of L-Arginine increases uterine placental circulation, decreases maternal blood pressure, and reduces platelet aggregation (19). L-Arginine prevents preeclampsia and increased blood pressure in patients with a high risk of preeclampsia. Administering L-Arginine obtains good results when given at 19-20 weeks of gestation. This L-Arginine therapy can be useful for patients at high risk of preeclampsia who arrive late at the first control (9). Some studies mention that high doses of L-arginine supplements can improve blood vessel function (23–25).

The mean fetal weight of the preeclampsia pregnant mouse model group given L-Arginine was higher than the preeclampsia pregnant mouse model group without L-Arginine. The results in this study are in accordance with previous studies which showed that administration of L-Arginine can increase body weight, uterus, placenta, and fetal weight. L-Arginine is a precursor in NO synthesis. The increase in fetal weight is thought to be caused by the contribution of NO to the placental blood vessels, as an important regulator in the regulation of placental perfusion. This causes an increase in fetal-maternal circulation through vasodilation, then increases volume and decreases blood viscosity in the fetus-mother circulation, thereby increasing fetal growth. (18). Another study showed that infusion of L-Arginine in animals during days 7-21 and 15-21 pregnancy increased the increase in protein in the fetus, thereby increasing fetal weight. (26).

Another study showed that L-Arginine supplementation increases the availability of various nutrients so that the concentration of several essential amino acids, such as methionine, isoleucine, leucine, and cysteine, and this condition supports fetal growth. (27). In India, oral administration of L-Arginine 3g per day is intended as prevention and management of IUGR and preeclampsia. This is only seen as an effort to prevent the condition, such as the use of Aspirin as an effort to prevent preeclampsia. Further research and review are still needed on L-Arginine to observe a way of prevention and treatment for preeclampsia and IUGR cases, with other factors such as the use of antihypertensive, antioxidants, nutritional regulation, and diet (22).

Although statistical test results were not significant, the difference in mean body weight of mice in each group in this study could be the basis for research to evaluate the effect of L-Arginine supplementation on fetal growth and body weight in mice models of preeclampsia. Several studies have shown that L-Arginine has a good effect on patients with a high risk of preeclampsia and patients who already have preeclampsia. Limitations of this study are likely to cause meaningless results. First, pregnancy termination is carried out on the 16th day, analogous to the end of the second trimester in humans, where the process of fetal development has only reached the stage of physical development and has not experienced optimal weight gain. Second, the data deviation is too large, with a very varied number of fetuses (2-9 fetuses) from each mouse parent affecting the mean fetal weight

results of each group of mice. Third, research with different doses has not been done to get a comparison of fetal body weight outcomes.

CONCLUSION

L-Arginine has been proven effectively repair endothelial damage and in this study seen from the diameter of the spiral arteries and fetal weight in preeclampsia mice model. Administering L-Arginine as NO precursor can improve hypoxia and placental ischemia as evidenced by the higher mean diameter of the spiral arteries fetal weight in the preeclampsia mouse models with L-Arginine compared to the normal pregnant mice group and the preeclampsia mouse models group without L-Arginine.

REFERENCES

1. World Health Organization. Prevention and treatment of preeclampsia and eclampsia. Geneva: WHO; 2011.
2. Royani I, As'ad S, Mappaware NA, Hatta M, Rabia. Effect of Ajwa Dates Consumption to Inhibit the Progression of Preeclampsia Threats on Mean Arterial Pressure and Roll-Over Test. *Biomed Res Int.* 2019;2019.
3. Lumbanraja SN. Determining the maternal characteristics that predicts the adverse outcomes for patients with preeclampsia. *J Univ Malaya Med Cent.* 2013;16(1):1-6.
4. Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. *Am J Obstet Gynecol.* 2007 Aug;197(2):176.e1-6.
5. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al. *Obstetric de Williams.* McGraw Hill Brasil; 2016.
6. Aprilia DN, Prasetyo B, Sulistiawati S. Correlation Between Nutritional Status of Pregnant Women Based on Upper Arm Circumference and Preeclampsia/Eclampsia Severity Degree at Jagir Public Health Center During January 2014 - March 2014. *Biomol Heal Sci J.* 2018;1(2):120-3.
7. Damayanti HE, Aditiawarman A. 25 (OH) D Inadequacy Has Different Pathway with VEGF in Increases the Risk of Severe Preeclampsia. *Maj Obstet Ginekol.* 2015;23(2):42-8.
8. Wardhana MP, Dachlan EG, Dekker G. Pulmonary edema in preeclampsia: an Indonesian case-control study. *J Matern neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet.* 2018 Mar;31(6):689-95.
9. Camarena Pulido EE, García Benavides L, Panduro

- Barón JG, Pascoe Gonzalez S, Madrigal Saray AJ, García Padilla FE, et al. Efficacy of L-arginine for preventing preeclampsia in high-risk pregnancies: a double-blind, randomized, clinical trial. *Hypertens pregnancy*. 2016;35(2):217–25.
10. Merviel P, Carbillon L, Challier J-C, Rabreau M, Beaufile M, Uzan S. Pathophysiology of preeclampsia: links with implantation disorders. *Eur J Obstet Gynecol Reprod Biol*. 2004 Aug;115(2):134–47.
 11. Shah DM. Preeclampsia: new insights. *Curr Opin Nephrol Hypertens*. 2007 May;16(3):213–20.
 12. Lukito J, Dewi P. Gambaran Histopatologi Arteri Spiralis Alas Plasenta pada Preeklampsia/Eklampsia dan Kehamilan Normotensif. *Maj Kedokt Nusant*. 2007;40(3):173–9.
 13. Situmorang PC, Ilyas S. Study of preeclampsia in placenta, kidney, and hepatic diseases. *Asian J Pharm Clin Res*. 2018;11(11):21–8.
 14. Lukas E, Chalid M, Miskad U, Bakri S. Comparison of p38 MAPK, soluble endoglin and endothelin-1 level in severe preeclampsia and HELLP syndrome patients. *Asian Pacific J Reprod*. 2019;8(2):83–7.
 15. Lubis MP, Hariman H, Lumbanraja SN, Bachtiar A. The role of placental growth factor, soluble endoglin, and uterine artery diastolic notch to predict the early onset of preeclampsia. *Open Access Maced J Med Sci*. 2019;7(7):1153–9.
 16. McCord N, Ayuk P, McMahon M, Boyd RCA, Sargent I, Redman C. Systemic arginine transport and NO production in peripheral blood mononuclear cells in pregnancy and preeclampsia. *Hypertens (Dallas, Tex 1979)*. 2006 Jan;47(1):109–15.
 17. Mittal R, Satwant K, Mittal N. L-arginine supplementation in intrauterine growth retardation. *Int J Pharm Chem Sci*. 2013;2(3):1569–72.
 18. Al-Bayati MA, Ahmad MA, Khamas W. The potential effect of L-arginine on mice placenta. *Adv Pharmacoevidemiol Drug Saf*. 2014;3(2):1–9.
 19. López-Jaramillo P, Arenas WD, García RG, Rincon MY, López M. The role of the L-arginine-nitric oxide pathway in preeclampsia. *Ther Adv Cardiovasc Dis*. 2008 Aug;2(4):261–75.
 20. Soetrisno S, Sulistyowati S, Wibowo A. L-arginine improves uterine spiral arterial wall thickness in mouse models of preeclampsia. *Universa Med*. 2017 Aug 11;36:131.
 21. Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D. Arginine dependence of tumor cells: targeting a chink in cancer's armor. *Oncogene*. 2016 Sep;35(38):4957–72.
 22. Hegde C V. The Use of L-Arginine in the Management of Pre-Eclampsia and Intrauterine Growth Restriction. *J Obstet Gynaecol India*. 2012 Feb;62(1):1–2.
 23. Böger RH. The pharmacodynamics of L-arginine. *J Nutr*. 2007 Jun;137(6 Suppl 2):1650S-1655S.
 24. Blum A, Porat R, Rosenschein U, Keren G, Roth A, Laniado S, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. *Am J Cardiol*. 1999 May;83(10):1488–90, A8.
 25. Ceremuzyński L, Chamiec T, Herbaczyński K, Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. *Am J Cardiol*. 1997 Aug;80(3):331–3.
 26. de Boo HA, van Zijl PL, Smith DEC, Kulik W, Lafeber HN, Harding JE. Arginine and mixed amino acids increase protein accretion in the growth-restricted and normal ovine fetus by different mechanisms. *Pediatr Res*. 2005 Aug;58(2):270–7.
 27. Lassala A, Bazer FW, Cudd TA, Datta S, Keisler DH, Satterfield MC, et al. Parenteral administration of L-arginine prevents fetal growth restriction in undernourished ewes. *J Nutr* [Internet]. 2010/05/26. 2010 Jul;140(7):1242–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/20505020>